Preventive and Curative treatment of malaria during pregnancy in Mali: Evaluation of the Healthcare Professionals based on the Malian National Malaria Control Program (NMCP) Guidelines
Malaria infections in pregnancy should be treated promptly with safe and efficacious antimalarial drugs to prevent harmful effects on the mother and fetus. To succeed, the Malian has developed NMCP guidelines for the management of malaria cases in pregnant women. The study aimed at the analysis of the prescription of antimalarial drugs based on the Mali's NMCP guidelines.
We conducted a cross-sectional study during malaria transmission season from June to August 2020. The sampling concerned all prescriptions for pregnant women containing at least one antimalarial drug.
The frequency of prescription of antimalarial drugs was 85%. 132 (74.16%) were preventive treatments and 46 (25.84%) curative treatments. 30 (90.91%) of pregnant women in the first trimester received one dose of Sulfadoxine-Pyrimethamine. 6 (12.5%) received three doses in the third trimester. Of the 46 antimalarial drugs prescribed for the treatment of uncomplicated malaria, 30 (65.22%) were Artemether-lumefantrine (tablet), 10 (21.74%) were Quinine (tablet). 29 (63.04%) were compliant with NMCP guidelines and 17 (36.96%) were not. The non-compliances concerned 3 prescriptions of Artemether-lumefantrine in the first trimester, 3 and 5 prescriptions of Quinine (tablet) in the second and third trimester respectively and at the end 2 and 4 non-compliances respectively for the prescription of injectable dosage forms of Quinine and Artesunate.
This study showed a great noncompliance with the Mali's NMCP guidelines in the prescription of antimalarial in pregnant women. Chemoprophylaxis should be prohibited in the first trimester.
Keywords: Curative and Preventive Treatment, Malaria in Pregnancy, Malaria Transmission, Mali
2. Walker PGT, ter Kuile FO, Garske T, Menendez C, Ghani AC. Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study. Lancet Glob Health. 2014; 2(8):e460-467. https://doi.org/10.1016/S2214-109X(14)70256-6
3. Kapisi J, Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, et al. Relationships between infection with Plasmodium falciparum during pregnancy, measures of placental malaria, and adverse birth outcomes. Malaria Journal. 5 oct 2017; 16(1):400 https://doi.org/10.1186/s12936-017-2040-4
4. Moore KA, Simpson JA, Scoullar MJL, McGready R, Fowkes FJI. Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta-analysis. Lancet Glob Health. 2017; 5(11):e1101 12. https://doi.org/10.1016/S2214-109X(17)30340-6
5. Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. The Lancet Infectious Diseases. 2007; 7(2):136 44. https://doi.org/10.1016/S1473-3099(07)70025-7
6. Wilby KJ, Ensom MHH. Pharmacokinetics of antimalarials in pregnancy: a systematic review. Clin Pharmacokinet. 2011; 50(11):705 23. https://doi.org/10.2165/11594550-000000000-00000
7. Nosten F, McGready R, Mutabingwa T. Case management of malaria in pregnancy. The Lancet Infectious Diseases. 2007; 7(2):118 25. https://doi.org/10.1016/S1473-3099(07)70023-3
8. World Health Organization. Guidelines for the treatment of malaria [Internet]. World Health Organization; 2015 [cité 30 sept 2021]. 313 p. Disponible sur: https://apps.who.int/iris/handle/10665/162441
9. Directives Nationales Pour La Prise En Charge Des Cas De Paludisme Au Mali.pdf.
10. Zurovac D, Rowe A, Ochola S, Noor A, Midia B, English M, et al. Predictors of the quality of health worker treatment practices for uncomplicated malaria at government health facilities in Kenya. International Journal of Epidemiology.2004; 33(5):1080 91. https://doi.org/10.1093/ije/dyh253
11. Eze UI, Eferakeya AE, Oparah AC, Enato EF. Assessment of prescription profile of pregnant women visiting antenatal clinics. Pharm Pract (Granada). 2007; 5(3):135 9. https://doi.org/10.4321/S1886-36552007000300007
12. Alemu BK, Wolle NN. Prescription drug use and potential teratogenicity risk among pregnant women attending maternal and child health clinic of Kemisse General Hospital, Northeast, Ethiopia. BMC Res Notes. 2019; 12(1):592. https://doi.org/10.1186/s13104-019-4641-1
13. Idowu OA, Mafiana CF, Sotiloye D. Traditional birth home attendance and its implications for malaria control during pregnancy in Nigeria. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2008; 102(7):679 84. https://doi.org/10.1016/j.trstmh.2008.03.020
14. Deen JL, von Seidlein L, Pinder M, Walraven GEL, Greenwood BM. The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2001; 95(4):424 8. https://doi.org/10.1016/S0035-9203(01)90204-4
15. Guidance on the use of international nonproprietary names (INNs) for pharmaceutical substances.pdf.
16. Revue des documents nationaux sur le paludisme pendant la grossesse dans cinq pays soutenus par l'Initiative Présidentielle contre le Paludisme (PMI).pdf.
17. WHO-RHR-18.05-fre.pdf [Internet]. [cité 30 sept 2021]. Disponible sur: http://apps.who.int/iris/bitstream/handle/10665/259955/WHO-RHR-18.05-fre.pdf;jsessionid=62A92FF210AD401D43F317E3762041B6?sequence=1
18. WHO/UCN/GMP/2021.01 Rev.1. WHO Guidelines for malaria [Internet]. 2021 [cité 30 sept 2021]. Disponible sur: https://www.who.int/publications-detail-redirect/guidelines-for-malaria
19. Luz TCB, Miranda ES, Freitas LF, Osório-de-Castro CGS. Prescriptions for uncomplicated malaria treatment among pregnant women in the Brazilian Amazon: evidences from the Mafalda Project. Rev Bras Epidemiol. 2013; 16(2):409 19. https://doi.org/10.1590/S1415-790X2013000200016
20. Rouamba T, Valea I, Bognini JD, Kpoda H, Mens PF, Gomes MF, et al. Safety Profile of Drug Use During Pregnancy at Peripheral Health Centres in Burkina Faso: A Prospective Observational Cohort Study. Drugs Real World Outcomes. 2018; 5(3):193 206. https://doi.org/10.1007/s40801-018-0141-1
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).